Literature DB >> 12806278

Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy.

Uluhan Sili1, M Helen Huls, Alan R Davis, Stephen Gottschalk, Malcolm K Brenner, Helen E Heslop, Cliona M Rooney.   

Abstract

Dendritic cells (DCs) have been shown to activate cytotoxic T-lymphocytes (CTLs) for many tumor and virus-associated antigens in vitro. In this study, the authors tested the feasibility of using DCs to expand polyclonal, cytomegalovirus (CMV)-specific CTL lines for adoptive immunotherapy. Two stimulations with DCs expressing pp65, the immunodominant antigen of CMV, effectively activated and expanded MHC-class I restricted, CMV-specific CTLs from peripheral blood mononuclear cells. However, limiting monocyte-derived DC numbers precluded the authors from expanding the CTLs to the numbers required for adoptive transfer protocols. Nonspecific stimulation methods failed to expand CTL lines specifically. However, the authors found that lymphoblastoid cell lines (LCLs) expressing pp65 expanded pp65-specific CTL lines without competition from EBV-specific CTLs. An unlimited source of antigen presenting cells that could present antigen in the appropriate MHC context emerged as a critical point for expansion of polyclonal, antigen-specific CTL lines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12806278     DOI: 10.1097/00002371-200305000-00008

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  21 in total

1.  Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity.

Authors:  Naoto Hirano; Marcus O Butler; Zhinan Xia; Sascha Ansén; Michael S von Bergwelt-Baildon; Donna Neuberg; Gordon J Freeman; Lee M Nadler
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

2.  Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.

Authors:  Lawrence G Lum; Mayur Ramesh; Archana Thakur; Subhashis Mitra; Abhinav Deol; Joseph P Uberti; Philip E Pellett
Journal:  Biol Blood Marrow Transplant       Date:  2012-02-05       Impact factor: 5.742

3.  Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus.

Authors:  Patrick J Hanley; Sharon Lam; Elizabeth J Shpall; Catherine M Bollard
Journal:  J Vis Exp       Date:  2012-05-07       Impact factor: 1.355

4.  An update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: a decade of cell therapy.

Authors:  Deborah Wood; Robin Wesselschmidt; Peiman Hematti; Adrian P Gee; Cliona Rooney; Leslie Silberstein; Myriam Armant; Larry Couture; John E Wagner; David H McKenna; Derek Hei; Traci Heath Mondoro; Lisbeth Welniak; Robert Lindblad
Journal:  Clin Transl Sci       Date:  2014-03-21       Impact factor: 4.689

5.  Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.

Authors:  Catherine M Bollard; Stephen Gottschalk; M Helen Huls; Ann M Leen; Adrian P Gee; Cliona M Rooney
Journal:  Cytotherapy       Date:  2011-03-01       Impact factor: 5.414

6.  Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.

Authors:  Minhtran Charlotte Ngo; Jun Ando; Ann M Leen; Sravya Ennamuri; Natalia Lapteva; Juan F Vera; Amelia Min-Venditti; Martha P Mims; Helen E Heslop; Catherine M Bollard; Stephen Gottschalk; Cliona M Rooney
Journal:  J Immunother       Date:  2014-05       Impact factor: 4.456

Review 7.  Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies.

Authors:  William Reed; Stephen J Noga; Adrian P Gee; Cliona M Rooney; John E Wagner; Jeffrey McCullough; David H McKenna; Theresa L Whiteside; Albert D Donnenberg; Acacia K Baker; Robert W Lindblad; Elizabeth L Wagner; Traci Heath Mondoro
Journal:  Transfusion       Date:  2008-12-23       Impact factor: 3.157

8.  Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

Authors:  Patrick J Hanley; Conrad Russell Young Cruz; Barbara Savoldo; Ann M Leen; Maja Stanojevic; Mariam Khalil; William Decker; Jeffrey J Molldrem; Hao Liu; Adrian P Gee; Cliona M Rooney; Helen E Heslop; Gianpietro Dotti; Malcolm K Brenner; Elizabeth J Shpall; Catherine M Bollard
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

9.  Stimulation by means of dendritic cells followed by Epstein-Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responses.

Authors:  F Zhu; G Ramadan; B Davies; D A Margolis; C A Keever-Taylor
Journal:  Clin Exp Immunol       Date:  2007-11-14       Impact factor: 4.330

10.  Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.

Authors:  Concetta Quintarelli; Gianpietro Dotti; Biagio De Angelis; Valentina Hoyos; Martha Mims; Luigia Luciano; Helen E Heslop; Cliona M Rooney; Fabrizio Pane; Barbara Savoldo
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.